On March 18, 2026, Cingulate Inc. reported its financial results for the year ending December 31, 2025, and announced that the USPTO allowed a patent for its ADHD treatment CTx-1301, which will be protected until May 2042.
AI Assistant
CINGULATE INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.